BioMarin Pharmaceutical Price Target Increased to $87.00 by Analysts at Jefferies Group (BMRN)
Equities research analysts at Jefferies Group boosted their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $83.00 to $87.00 in a research note issued to investors on Wednesday, AnalystRatings.NET reports. Jefferies Group’s price target would indicate a potential upside of 13.89% from the stock’s previous close.
Shares of BioMarin Pharmaceutical (NYSE:BMRN) traded down 0.05% during mid-day trading on Wednesday, hitting $76.35. 1,269,120 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 52 week low of $53.14 and a 52 week high of $80.67. The stock has a 50-day moving average of $70.57 and a 200-day moving average of $68.82. The company’s market cap is $10.858 billion.
A number of other firms have also recently commented on BMRN. Analysts at Wedbush raised their price target on shares of BioMarin Pharmaceutical from $72.00 to $74.00 in a research note on Tuesday. Separately, analysts at Barclays downgraded shares of BioMarin Pharmaceutical from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. They now have a $73.00 price target on the stock, down previously from $75.00. Finally, analysts at Piper Jaffray reiterated an “overweight” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, November 27th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $77.00.
BioMarin Pharmaceutical Inc (NYSE:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.